



Date: 30 May 2025

National Stock Exchange of India Limited, Compliance Department, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India E-mail: takeover@nse.co.in Stock Code: NSE – HCG	BSE Limited, Compliance Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001, Maharashtra, India E-mail: corp.relations@bseindia.com Stock Code: BSE – 539787
---	---

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”).

1. This is in furtherance to the intimation made to the stock exchanges on February 23, 2025, with respect to execution of inter alia the below:
 - (a) share purchase agreement between Aceso Company Pte. Ltd. (“**Seller**”), Hector Asia Holdings II Pte. Ltd. (“**Purchaser 1**”) and KIA EBT II Scheme 1 (“**Purchaser 2**”) (Purchaser 1 and Purchaser 2 collectively, “**Purchasers**”) and HealthCare Global Enterprises Limited (“**Company**”) for the sale of upto 54% of the diluted voting share capital of the Company from Seller to the Purchasers (“**SPA**”); and
 - (b) promoter agreement between the Company, BSA Promoter Group (i.e. Dr. B.S. Ajaikumar, Ms. Bhagya A Ajaikumar, Ms. Anjali Ajaikumar Rossi, Ms. Aagnika Ajaikumar and Ms. Asmitha Ajaikumar) and the Purchasers, to record the inter-se rights and obligations of the Purchasers and the BSA Promoter Group (“**Promoter Agreement**”).
2. We wish to inform you that the Company has signed: (a) supplementary agreement to the SPA on May 30, 2025 (“**Supplementary SPA**”); and (b) supplementary agreement to the Promoter Agreement on May 30, 2025 (“**Supplementary Promoter Agreement**”).
3. Pursuant to the Supplementary SPA, the parties therein have clarified and detailed the process for remittance and withholding tax computation and settlement under the SPA.
4. Pursuant to the Supplementary Promoter Agreement, the parties therein have agreed to prescribe June 30, 2025 as the effective date for resignation of the BSA Promoter Group from their directorships and key managerial positions in certain direct and indirect subsidiaries, of the Company, and limited liability partnerships, which partnerships are controlled by the Company (“**Target Group Entities**”).
5. Details as required under Regulation 30 of the SEBI (LODR) Regulations read with SEBI master circular dated 11 July 2023, bearing reference no. SEBI/HO/CFD/PoD2/CIR/P/2023/120, and SEBI circular dated 13 July 2023, bearing reference no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123, are set out in:

HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489



- Annexure A – Supplementary SPA; and
- Annexure B – Supplementary Promoter Agreement.

The aforesaid details may also be accessed on the website of the Company at <https://www.hcgoncology.com/>.

Kindly take this on record and acknowledge receipt of the intimation.

Thanking you,

FOR HEALTHCARE GLOBAL ENTERPRISES LIMITED

Sunu Manuel
Company Secretary & Compliance Officer

Encl: As above



Annexure A

Disclosure in respect of the Supplementary Agreement to Share Purchase Agreement between Aceso Company Pte. Ltd. (“Seller”), Hector Asia Holdings II Pte. Ltd. (“Purchaser 1”) and KIA EBT II Scheme 1 (“Purchaser 2”) (Purchaser 1 and Purchaser 2 collectively, “Purchasers”) and HealthCare Global Enterprises Limited (“Company”) (“Supplementary SPA”) in terms of Regulation 30 of the SEBI Listing Regulations read with Annexure I of the SEBI Disclosure Circular

SL No	Particulars	Details
1	If the listed entity is a party to the agreement, i. details of the counterparties (including name and relationship with the listed entity).	Seller: Aceso Company Pte. Ltd. (“ Seller ”). Seller was part of the promoter / promoter group of the Company at the time of entering into the Supplementary SPA. Purchasers: Hector Asia Holdings II Pte. Ltd. (“ Purchaser 1 ”) and KIA EBT II Scheme 1 (“ Purchaser 2 ”) (Purchaser 1 and Purchaser 2 collectively, “ Purchasers ”). The Purchasers (at the time of entering into the Supplementary SPA) were not a related party to the Company.
2	Purpose of entering into the agreement	Refer to the disclosures made to the Stock Exchanges on 23 February 2025, as part of intimation on signing the SPA and paragraph 11 below.
3	Shareholding, if any, in the entity with whom the agreement is executed	None
4	Significant terms of the agreement (in brief)	Refer to the disclosures made to the Stock Exchanges on 23 February 2025, as part of intimation on signing the SPA and paragraph 11 below.
5	Extent and the nature of impact on management or control of the listed entity	Refer to the disclosures made to the Stock Exchanges on 23 February 2025, as part of intimation on signing the SPA and paragraph 11 below.
6	Details and quantification of the restriction or liability imposed upon the listed entity	Refer to the disclosures made to the Stock Exchanges on 23 February 2025, as part of intimation on signing the SPA and paragraph 11 below.
7	Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship;	Refer to the disclosures made to the Stock Exchanges on 23 February 2025, as part of intimation on signing the SPA and paragraph 11 below.

HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489



8	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”	No
9	In case of issuance of shares to the parties, details of issue price, class of shares issued	Not applicable
10	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.	Refer to the disclosures made to the Stock Exchanges on 23 February 2025, as part of intimation on signing the SPA.
11	In case of rescission, amendment or alteration, listed entity shall disclose additional details to the stock exchange(s):	
	i. name of parties to the agreement;	The Supplementary agreement has been entered into by and amongst the same parties to the SPA namely, Aceso, the Purchasers, and the Company.
	ii. nature of the agreement;	The Supplementary agreement is in the nature of an agreement to supplement the SPA.
	iii. date of execution of the agreement;	The Supplementary SPA is executed on 30 May 2025.
	iv. details and reasons for amendment or alteration and impact thereof (including impact on management or control and on the restriction or liability quantified earlier); reasons for rescission and impact thereof (including impact on management or control and on the restriction or liability quantified earlier).	As the Seller and the Purchaser 1 are non-resident entities, and the payment of consideration will take place outside India in accordance with the SPA, the Supplementary SPA has been executed to clarify and detail the foreign currency conversion rates and withholding tax computation and settlement process that would be applicable. For the avoidance of doubt it is clarified that there is no change to the Per Share Price in the SPA.



Annexure B

Disclosure in respect of the Supplementary Agreement dated 30 May 2025 (“Supplementary Promoter Agreement”) to the Promoters’ Agreement dated 23 February 2025, between HealthCare Global Enterprises Limited (“Company”), BSA Promoter Group (as defined below), Hector Asia Holdings II Pte. Ltd. (“Purchaser 1”) and KIA EBT II Scheme 1 (“Purchaser 2”) (“Promoter Agreement”), in terms of Regulation 30 of the SEBI Listing Regulations, read with Annexure I of the SEBI Disclosure Circular

Sl No	Particulars	Details
1	If the listed entity is a party to the agreement, i. details of the counterparties (including name and relationship with the listed entity).	(i) BSA Promoter Group (i.e. Dr. B.S. Ajaikumar, Ms. Bhagya A Ajaikumar, Ms. Anjali Ajaikumar Rossi, Ms. Aagnika Ajaikumar and Ms. Asmitha Ajaikumar), who are is part of the promoter / promoter group of the Company; (ii) Purchaser 1 and Purchaser 2 (Purchaser 1 and Purchaser 2 collectively, “ Purchasers ”). The Purchasers (at the time of entering into the Supplementary Promoter Agreement) are not a related party to the Company.
2	Purpose of entering into the agreement	Refer to the disclosures made to the Stock Exchanges on 23 February 2025, as part of intimation on signing the Promoter Agreement and paragraph 11 below.
3	Shareholding, if any, in the entity with whom the agreement is executed	BSA Promoter Group holds 10.87% of the share capital of the Company. The Purchasers do not hold any shares in the Company.
4	Significant terms of the agreement (in brief)	Refer to the disclosures made to the Stock Exchanges on 23 February 2025, as part of intimation on signing the Promoter Agreement and paragraph 11 below.
5	Extent and the nature of impact on management or control of the listed entity	Refer to the disclosures made to the Stock Exchanges on 23 February 2025, as part of intimation on signing the Promoter Agreement and paragraph 11 below.
6	Details and quantification of the restriction or liability imposed upon the listed entity	Not applicable
7	Whether, the said parties are related to promoter / promoter group / group companies in any manner? If yes, nature of relationship	Refer to the disclosures made to the Stock Exchanges on 23 February 2025, as part of intimation on signing the Promoter Agreement and paragraph 11 below.

HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489



8	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”	No
9	In case of issuance of shares to the parties, details of issue price, class of shares issued	Not applicable
10	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements etc.	Refer to the disclosures made to the Stock Exchanges on 23 February 2025, as part of intimation on signing the Promoter Agreement.
11	In case of rescission, amendment or alteration, listed entity shall disclose additional details to the stock exchange(s):	
	(i) name of parties to the agreement	The Supplementary Promoter Agreement has been entered into by and amongst the same parties to the Promoter Agreement, namely, Company, BSA Promoter Group and the Purchasers.
	(ii) nature of the agreement	The Supplementary Promoter Agreement is in the nature of an amendment agreement to modify and supplement the Promoter Agreement.
	(iii) date of execution of the agreement	The Supplementary Promoter Agreement is executed on 30 May 2025.
	(iv) details and reasons for amendment or alteration and impact thereof (including impact on management or control and on the restriction or liability quantified earlier); reasons for rescission and impact thereof (including impact on management or control and on the restriction or liability quantified earlier).	<p>As per the provisions of the Promoter Agreement, on and from the Effective Date (as defined in the disclosure made on 23 February 2025), all members of the BSA Promoter Group were required to resign from any and all positions held by them in certain direct and indirect subsidiaries, of the Company, and limited liability partnerships, which partnerships are controlled by the Company.</p> <p>Pursuant to the Supplementary Promoter Agreement this provision has been amended to provide that the BSA Promoter Group shall resign from the positions held by them in the above discussed entities with effect from June 30, 2025 (instead of the Effective Date of the Promoter Agreement) in accordance with the terms of the Promoter Agreement. Further, the Supplementary Promoter Agreement also includes the continuation of BSA and Anjali on the board of BACC Healthcare Private Limited.</p>

HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489